1. Home
  2. KWR vs MESO Comparison

KWR vs MESO Comparison

Compare KWR & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KWR
  • MESO
  • Stock Information
  • Founded
  • KWR 1918
  • MESO 2004
  • Country
  • KWR United States
  • MESO Australia
  • Employees
  • KWR N/A
  • MESO N/A
  • Industry
  • KWR Major Chemicals
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KWR Industrials
  • MESO Health Care
  • Exchange
  • KWR Nasdaq
  • MESO Nasdaq
  • Market Cap
  • KWR 1.8B
  • MESO 1.4B
  • IPO Year
  • KWR 1985
  • MESO N/A
  • Fundamental
  • Price
  • KWR $103.37
  • MESO $10.97
  • Analyst Decision
  • KWR Strong Buy
  • MESO Buy
  • Analyst Count
  • KWR 4
  • MESO 4
  • Target Price
  • KWR $157.75
  • MESO $18.00
  • AVG Volume (30 Days)
  • KWR 151.4K
  • MESO 156.4K
  • Earning Date
  • KWR 05-01-2025
  • MESO 02-26-2025
  • Dividend Yield
  • KWR 1.87%
  • MESO N/A
  • EPS Growth
  • KWR N/A
  • MESO N/A
  • EPS
  • KWR 5.29
  • MESO N/A
  • Revenue
  • KWR $1,812,841,000.00
  • MESO $5,670,000.00
  • Revenue This Year
  • KWR $3.06
  • MESO $152.37
  • Revenue Next Year
  • KWR $5.01
  • MESO $336.12
  • P/E Ratio
  • KWR $19.63
  • MESO N/A
  • Revenue Growth
  • KWR N/A
  • MESO N/A
  • 52 Week Low
  • KWR $95.91
  • MESO $5.78
  • 52 Week High
  • KWR $197.03
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • KWR 42.34
  • MESO 44.34
  • Support Level
  • KWR $99.18
  • MESO $10.77
  • Resistance Level
  • KWR $107.00
  • MESO $11.61
  • Average True Range (ATR)
  • KWR 3.93
  • MESO 0.47
  • MACD
  • KWR 0.90
  • MESO 0.09
  • Stochastic Oscillator
  • KWR 41.57
  • MESO 27.68

About KWR Quaker Houghton

Quaker Houghton manufactures and sells a variety of industrial process fluids. The product portfolio of the company includes metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die-cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids and surface treatment chemicals. The geographic segments of the company include America, EMEA, Asia/Pacific, and Global Specialty Businesses. The majority of the revenue is earned from America.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: